Parallel 6 Clinical Reach Mobile Enterprise Platform and Sentrian Remote Patient Intelligence Make Remote Patient Monitoring Personal
SAN DIEGO (June 15, 2015) --- Parallel 6, an innovator in enterprise mobile engagement and management solutions, and Sentrian™, the Remote Patient Intelligence™ company aspiring to eliminate all preventable hospitalization, announced today as technology partners, Clinical Reach’s Reachlink Connector will send patient data securely from the palm of the patients hand to Sentrian’s remote patient monitoring platform (Sentrian RPI). Parallel 6 will power Sentrian mobile applications to help care teams better engage with chronic disease patients, turning patient self-report data into another data input for the Sentrian powerful analytics engine.
Clinical Reach is a HIPAA compliant, end-to-end patient lifecycle management and engagement platform. Its ReachLink Connector’s ability to securely collect large amounts of patient data in real-time via mobile and send through to the Sentrian RPI platform will securely serve both patients and care teams in multiple languages around the world.
“As we combine our solution with Sentrian’s award winning RPI platform, our technology changes the way patients and healthcare providers evaluate their health,” said CEO of Parallel 6, Allan Camaisa. “Our technologies are empowering people all over the world to securely communicate.”
“We’re always seeking to provide our care teams and patients with the most effective interaction tools and platforms,” said Co-Founder, Chief Executive Officer of Sentrian, Dean Sawyer. “Together, we’re helping improve patient outcomes, reduce avoidable costs and improve patient satisfaction for those dealing with complex chronic disease.”
Parallel 6 is an exhibitor at the DIA 2015 51st Annual Meeting gathering in Washington, D.C. Booth #1957. Parallel 6 CEO and Chairman, Allan Camaisa and President, CTO and Founder, David Turner, will be available for interviews and a demo of their technology platform.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
